AxoGen, Inc. (AXGN)
-OTC BB 4.50 
0.06(1.35%) Jun 19, 9:30AM EDT
| Prev Close: | 4.44 |
|---|
| Open: | 4.50 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 6.55 |
|---|
| Beta: | 0.71 |
|---|
| Next Earnings Date: | 12-Aug-13 |
|---|
| Day's Range: | 4.50 - 4.50 |
|---|
| 52wk Range: | 2.06 - 6.25 |
|---|
| Volume: | 100 |
|---|
| Avg Vol (3m): | 7,755 |
|---|
| Market Cap: | 50.13M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.97 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AxoGen Sets Stage For Growth In Canadaat Seeking Alpha(Wed, Jun 5)
- AxoGen, Inc. Announces Health Canada Approval for AxoGuard(R) Nerve Connector and AxoGuard(R) Nerve ProtectorGlobeNewswire(Tue, Jun 4)
- AxoGen, Inc. Announces Presentation of Avance(R) Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand CongressGlobeNewswire(Wed, May 29)
- AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of DefenseGlobeNewswire(Thu, May 23)
- AxoGen, Inc. Files Form S-1 Registration StatementGlobeNewswire(Tue, May 14)
- AXOGEN, INC. FinancialsEDGAR Online Financials(Sat, May 4)
- AxoGen' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- AxoGen, Inc. Announces CE Mark Approval for AxoGuard(R) Nerve Protector and AxoGuard(R) Nerve ConnectorGlobeNewswire(Wed, May 1)
- AXOGEN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 1)
- AxoGen, Inc. Reports First Quarter 2013 Financial ResultsGlobeNewswire(Tue, Apr 30)
- AXOGEN, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Apr 30)
- Healing Nerve Damage With CadaversTheStreet(Mon, Apr 29)
- AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference CallGlobeNewswire(Wed, Apr 24)
- AxoGen, Inc. Announces Presentation of Avance(R) Nerve Graft Data at American Association of Plastic Surgeons 2013 Annual MeetingGlobeNewswire(Fri, Apr 19)
- AxoGen, Inc. to Host Panel on Nerve Repair at the American College of Oral and Maxillofacial Surgeons 2013 Annual MeetingGlobeNewswire(Tue, Apr 16)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6.05 |
|---|
| Ex-Dividend Date: | 27-Jan-10 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.02 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.28 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
AxoGen, Inc. operates as a regenerative medicine company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions.
View More